Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

Most acute myeloid leukemia (AML) cells are argininosuccinate synthetase‐deficient. Pegylated arginine deiminase (ADI‐PEG20) monotherapy depletes circulating arginine, thereby selectively inducing tumor cell death. ADI‐PEG20 was shown to induce complete responses in ~10% of relapsed/refractory or po...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Hui‐Jen, Hsiao, Hui‐Hua, Hsu, Ya‐Ting, Liu, Yi‐Chang, Kao, Hsiao‐Wen, Liu, Ta‐Chih, Cho, Shih‐Feng, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John S., Kuo, Ming‐Chung, Chen, Tsai‐Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085967/
https://www.ncbi.nlm.nih.gov/pubmed/33787078
http://dx.doi.org/10.1002/cam4.3871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085967/
https://www.ncbi.nlm.nih.gov/pubmed/33787078
http://dx.doi.org/10.1002/cam4.3871

Ejemplares similares